United States Patent and Trademark Office Issues Broader Claims for ArunA Biomedical’s Exclusively Licensed Stem Cell Technology

Aruna Biomedical, Inc., the exclusive worldwide commercial licensee of stem cell technology developed at the University of Georgia (UGA), announced today that the US Patent and Trademark Office will issue a new patent mid-month that enlarges the scope of the licensed patent portfolio to include primate pluripotent stem cells.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Implications of these allowed claims could effectively address significant gaps in early stage drug development timelines and could lead to a more efficient means to identify environmental and chemical toxicants.

Athens, GA (PRWEB) May 11, 2012

ArunA Biomedical first announced its technology license agreement with the UGA Research Foundation, Inc. for the commercialization of neural cells derived from human embryonic stem cells in May 2007. Since then the company has developed proprietary manufacturing techniques that allow for consistent propagation of billions of neural cells in a single production run. The increased breadth of the newly allowed claims includes a method of propagating neural cells from primate pluripotent stem cells including human induced pluripotent stem cells.

“The broadened claims of our licensed technology will further enhance ArunA’s position as a leader in the rapidly expanding stem cell research tools market.” said ArunA co-founder and Georgia Research Alliance Eminent Scholar, Steven Stice. “Utilizing the manufacturing expertise we’ve developed for human embryonic stem cell derived neural cells and now the inclusion of cells across a wider range of tissue sources including disease and patient specific pluripotent lines promises to have positive implications for researchers’ quest for cellular models that demonstrate consistency and high quality.”

“Implications of these allowed claims could effectively address significant gaps in early stage drug development timelines and could lead to a more efficient means to identify environmental and chemical toxicants. Investigators have been attracted to ArunA’s unique human cells because of their consistency, scalability and adaptability of use. We’ll now be able to enlarge the scope of our product and service offerings by applying additional tissue sources to our neural cell format.” said, David Dodd, ArunA Director and life science industry leader.

About ArunA Biomedical: Aruna Biomedical, Inc. is a privately held biotechnology company dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research.

This press release contains forward-looking statements regarding the company’s potential impact on scientific research, patient therapies and product development. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.

Press contact:
Tracey Worthington Stice
Vice President of Operations
Aruna Biomedical, Inc.
425 River Road
Athens, GA 30602
Office: 706-542-9191
Email: tstice(at)arunabiomedical(dot)com
Website: http://www.arunabiomedical.com


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn

Attachments